Syncell Launches Global Discovery CRO Service to Unlock Drug Targets With Nanoscopic Proteomics

• Syncell Inc., a next-generation proteomics technology company with operations in Livermore, California and Taipei, Taiwan, has commercially launched Syncell Discovery Services — a global, end-to-end sample-to-discovery CRO program that gives biopharma, translational research organizations, and academic institutions direct access to subcellular spatial proteomic profiling via its proprietary Microscoop Mint platform.

• The service integrates Syncell’s Microscoop Mint platform and Synlight reagents with Thermo Fisher Scientific’s Orbitrap Astral mass spectrometer to deliver unbiased, nanoscopic proteomic insights — enabling drug target discovery, biomarker identification, and disease biology research at a resolution that conventional spatial proteomics, laser capture, and proximity labeling approaches cannot achieve.

Syncell Inc., a leader in next-generation proteomics analysis, has announced the commercial launch of Syncell Discovery Services, a global sample-to-discovery CRO program that provides biopharma companies, translational research organizations, and academic institutions with outsourced access to the company’s Microscoop Mint platform. The service was announced on May 28, 2026, from Livermore, California and Taipei, Taiwan, marking Syncell’s transition from a platform technology developer to an active CRO service provider for drug discovery programs.

Syncell Discovery Services operates as an end-to-end outsourced workflow. Sponsors submit samples directly to Syncell and receive subcellular spatial proteomic profiling data, biological replicates, quality control analysis, and expert scientific interpretation — without requiring in-house access to the Microscoop Mint platform or the specialized expertise needed to operate it. The integrated workflow combines Syncell’s proprietary Microscoop Mint platform and Synlight reagents for spatial protein purification with Thermo Fisher Scientific’s ultra-sensitive Orbitrap Astral mass spectrometer, delivering proteome-wide protein identification at subcellular spatial resolution that goes beyond what conventional spatial proteomics, laser capture, and proximity labeling approaches can achieve.

For biopharma sponsors working in oncology, neuroscience, immunology, and cell biology, the CRO service is designed to address a specific gap in early-stage drug discovery: the inability of existing tools to resolve protein biology features at the nanoscopic level. Many indications currently have only one or two known biomarkers, leaving a significant portion of potentially actionable targets inaccessible to conventional methods. Syncell’s platform identifies proteins at specific subcellular locations — including proteins not previously known to be present at a site of interest — providing sponsors with richer, more unbiased target landscapes to inform lead identification and prioritization decisions.

The service is structured across two engagement tiers. Signature Discovery covers proteomic characterization of a single region, phenotype, or condition for exploratory biology, pathway analysis, and early-stage target discovery. Comparative Profiling delivers differential proteomic analysis across conditions, treatment groups, or disease states. Both programs include expert scientific support and are designed to produce decision-ready biological insight rather than raw data output. A pilot phase of Syncell Discovery Services prior to commercial launch demonstrated strong early traction, with demand outpacing capacity and customers identifying proteins not previously detected at their sites of interest.

“Demand quickly outpaced capacity, with customers identifying proteins not previously known to be at their site of interest. That traction has also translated into growing pharma interest in the Microscoop Mint platform itself.”

Nikhil Rao, PhD, Chief Commercial Officer, Syncell